Phospho-TP53 (S366) Antibody

What is the Phospho-TP53 (S366) Antibody and what epitope does it recognize?

The Phospho-TP53 (S366) Antibody is a rabbit polyclonal antibody that specifically recognizes the p53 protein when phosphorylated at serine 366. The immunogen used for producing this antibody is typically a synthesized phosphopeptide derived from human p53 surrounding the phosphorylation site of Ser366, corresponding to amino acid range 331-380 . This antibody enables researchers to specifically detect post-translational modifications of p53 that occur in response to cellular stress and DNA damage.

The specificity of this antibody for the phosphorylated form of p53 at S366 is critical for distinguishing this specific post-translational modification from other phosphorylation events on the p53 protein. Most commercially available versions are validated through multiple techniques to ensure they do not cross-react with unphosphorylated p53 or with p53 phosphorylated at other serine residues .

What are the validated applications for Phospho-TP53 (S366) Antibody?

The Phospho-TP53 (S366) Antibody has been validated for multiple laboratory applications:

For optimal results in Western blotting applications, researchers should follow these methodological considerations:

• Use freshly prepared lysates when possible

• Include phosphatase inhibitors in lysis buffers to preserve phosphorylation status

• Consider using positive controls such as HeLa cells treated with DNA-damaging agents like doxorubicin, which induce phosphorylation at S366

The antibody has demonstrated reactivity specifically with human p53, allowing for studies in human cell lines and tissue samples .

What is the biological significance of p53 phosphorylation at serine 366?

Phosphorylation of p53 at serine 366 represents a critical regulatory mechanism in the p53 signaling pathway. Research has revealed that:

• IKK2 (IκB kinase 2) phosphorylates p53 at serines 362 and 366, which facilitates p53 degradation independent of the canonical Mdm2 pathway and NF-κB activation

• This phosphorylation provides an alternative mechanism for attenuating p53 response after DNA damage

• S366 phosphorylation occurs with different kinetics compared to other phosphorylation events (such as S15 phosphorylation by ATM), suggesting it plays a role in the resolution of p53 activity following DNA damage response

Functionally, cells expressing p53 with mutations at both S362 and S366 (S362A/S366A, referred to as p53 AA) demonstrate higher p53 stability compared to wild-type p53, resulting in:

• Enhanced p21 expression

• Increased G1 cell cycle arrest (55% vs. 44% in wild-type expressing cells)

• Prolonged p53 activity

This suggests that phosphorylation at these sites regulates p53 turnover and limits its activity during the recovery phase after DNA damage.

How can researchers distinguish between IKK2-mediated and Chk2-mediated phosphorylation of p53 at S366?

Distinguishing between different kinases responsible for S366 phosphorylation requires careful experimental design:

Methodological approach:

• Genetic models: Utilize IKK2-deficient cells compared to wild-type cells. Research has shown that doxorubicin treatment increases S366 phosphorylation in wild-type MEF cells but not in IKK2-deficient cells . Importantly, Chk2 activation remains normal in IKK2-deficient cells, allowing researchers to differentiate between these two kinases.

• Kinetic analysis: Monitor the phosphorylation timing, as different kinases phosphorylate p53 with different kinetics:

  • ATM-mediated phosphorylation (e.g., at S15) occurs rapidly after DNA damage

  • IKK2-mediated S366 phosphorylation shows delayed kinetics, developing over 3-4 hours following DNA damage

  • This temporal difference can help identify which kinase is responsible under specific conditions

• Inhibitor studies: Use selective IKK2 inhibitors in conjunction with the Phospho-TP53 (S366) antibody to confirm IKK2's role in phosphorylating this site under various experimental conditions.

• In vitro kinase assays: Perform comparative in vitro kinase assays with purified IKK2 and Chk2, using the phospho-specific antibody to detect phosphorylation of wild-type versus mutant (S366A) p53 substrates .

What are the technical considerations for optimizing Phospho-TP53 (S366) Antibody use in various experimental contexts?

Sample preparation optimization:

• Phosphorylation preservation:

  • Rapid sample processing is critical to prevent dephosphorylation

  • Include phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in lysis buffers

  • For tissue samples, immediate snap-freezing following collection is recommended

• Background reduction:

  • Optimize blocking conditions (5% BSA is often more effective than milk for phospho-epitopes)

  • Consider using phospho-blocking peptides as competitive controls

  • Test multiple antibody dilutions to identify optimal signal-to-noise ratio

• Cross-reactivity assessment:

  • Include negative controls, such as p53-deficient cells or S366A mutant p53 expressing cells

  • For IHC applications, always include both positive and negative control tissues

Storage considerations:

• Store the antibody at -20°C for long-term preservation

• For frequent use, aliquot and store at 4°C for up to one month

• Avoid repeated freeze-thaw cycles to maintain antibody performance

How can Phospho-TP53 (S366) Antibody be integrated into comprehensive p53 post-translational modification studies?

Multiplex analysis approach:

• Sequential immunoblotting:

  • Strip and reprobe membranes with antibodies targeting different p53 phosphorylation sites

  • Compare phosphorylation patterns at S15, S20, S46, and S366 to establish temporal relationships

  • This approach reveals the sequence of phosphorylation events and can identify "phosphorylation signatures" associated with different cellular responses

• Antibody panel selection:
  Combine Phospho-TP53 (S366) with other site-specific antibodies to create a comprehensive panel:

  Phosphorylation Site	Kinase	Functional Significance
  S15	ATM, ATR, DNA-PK	Initial response to DNA damage; reduces MDM2 binding
  S20	Chk1, Chk2	Enhances tetramerization and stability
  S46	HIPK2, p38	Regulates apoptotic response
  S366	IKK2, Chk2	Facilitates p53 degradation; resolves p53 response

• Mass spectrometry integration:

  • Use immunoprecipitation with the Phospho-TP53 (S366) antibody followed by mass spectrometry

  • This enables identification of proteins that specifically interact with p53 when phosphorylated at S366

  • Can reveal novel regulatory complexes involved in p53 modulation after DNA damage

What experimental approaches can resolve contradictory data regarding the role of S366 phosphorylation in p53 regulation?

Reconciling conflicting observations:

• Context-dependent analysis:

  • Compare S366 phosphorylation effects across different cell types (normal vs. cancer cells)

  • Evaluate under various stress conditions (DNA damage, oxidative stress, oncogene activation)

  • This approach can identify cell-type or stimulus-specific responses

• Combinatorial mutation studies:

  • Generate and analyze p53 mutants with combinations of phosphorylation site mutations

  • For example, compare S366A single mutant to S362A/S366A double mutant, or combine with mutations at other sites

  • This addresses potential compensatory or cooperative effects between different phosphorylation sites

• Temporal dynamics investigation:

  • Design time-course experiments to capture the complete phosphorylation-dephosphorylation cycle

  • Research shows S366 phosphorylation occurs with different kinetics compared to other sites like S15

  • Use the Phospho-TP53 (S366) antibody to track phosphorylation over time in response to DNA damage

• Pathway cross-talk evaluation:

  • Investigate the relationship between IKK2 activation, NF-κB signaling, and p53 phosphorylation

  • Although IKK2 can regulate p53 through NF-κB-mediated Mdm2 expression, research shows S366 phosphorylation provides an alternative, NF-κB-independent mechanism

  • Use pathway-specific inhibitors to dissect these interconnected processes

What are the most effective strategies for validating Phospho-TP53 (S366) Antibody specificity?

Multi-stage validation protocol:

• Genetic controls:

  • Use p53-null cells as negative controls

  • Compare signal between wild-type p53 and S366A mutant expressing cells after DNA damage induction

  • Utilize siRNA/shRNA to knockdown p53 and confirm signal reduction

• Phosphatase treatment:

  • Treat duplicate samples with lambda phosphatase before immunoblotting

  • This should eliminate signal from the phospho-specific antibody while total p53 signal remains

  • Serves as a definitive control for phospho-specificity

• Peptide competition:

  • Pre-incubate antibody with phosphorylated and non-phosphorylated peptides

  • Only the phosphorylated peptide should competitively inhibit antibody binding

  • Compare signal reduction between phospho and non-phospho peptide competition

• Cross-reactivity assessment:

  • Test antibody against panels of phosphorylated proteins

  • Particularly important when examining closely related phosphorylation sites (e.g., S362 vs. S366)

  • Confirmation using orthogonal methods like mass spectrometry is ideal for absolute validation

How should researchers interpret changes in p53 S366 phosphorylation in the context of DNA damage response studies?

Integrated analysis framework:

How can Phospho-TP53 (S366) Antibody contribute to understanding cancer-specific p53 regulation?

Advanced cancer research applications:

• Tumor-specific phosphorylation patterns:

  • Compare S366 phosphorylation patterns across different cancer types

  • Analyze correlation with p53 mutation status (wild-type vs. mutant)

  • Evidence suggests the GAS41–PP2CP complex, which is amplified in cancers, interacts with S366 phosphorylation to regulate p53

• Therapeutic response monitoring:

  • Track S366 phosphorylation before and after chemotherapy treatment

  • Correlate changes with treatment outcomes and resistance development

  • This may help identify predictive biomarkers for therapy response

• Combination with mutational analysis:

  • Use the antibody to study how common p53 mutations affect phosphorylation patterns

  • Investigate whether mutant p53 shows altered S366 phosphorylation compared to wild-type

  • This could reveal how mutations disrupt normal regulatory mechanisms

• Analysis of phosphorylation in p53 reactivation strategies:

  • Monitor S366 phosphorylation during treatment with drugs that reactivate mutant p53

  • Study how phosphorylation at this site affects the efficacy of p53-targeted therapies

  • May provide insights for optimizing combination treatment strategies

What methodological approaches can improve detection sensitivity for low-abundance phosphorylated p53?

Enhanced detection strategies:

• Signal amplification methods:

  • Utilize tyramide signal amplification for IHC applications

  • Consider proximity ligation assays to detect interactions between phosphorylated p53 and binding partners

  • These approaches can significantly enhance detection sensitivity

• Enrichment techniques:

  • Implement phosphoprotein enrichment prior to Western blotting

  • Use immunoprecipitation with total p53 antibodies followed by phospho-specific detection

  • Consider titanium dioxide or IMAC (immobilized metal affinity chromatography) enrichment for mass spectrometry studies

• Single-cell analytical methods:

  • Apply the antibody in single-cell Western blotting

  • Explore imaging flow cytometry for simultaneous detection of multiple phosphorylation sites

  • These approaches help address cellular heterogeneity that may mask phosphorylation events in bulk analysis

• Digital detection platforms:

  • Consider digital ELISA platforms for ultrasensitive protein detection

  • These systems can detect femtomolar concentrations of proteins

  • Particularly valuable for detecting phosphorylated p53 in limited patient samples

What is the recommended workflow for reproducible phospho-p53 (S366) detection?

Standardized research protocol:

• Optimal sample preparation:

  • Harvest cells at appropriate timepoints after treatment (3-4 hours after DNA damage for peak IKK2-mediated phosphorylation)

  • Use lysis buffer containing protease and phosphatase inhibitors

  • Process samples quickly and maintain cold temperatures throughout

• Application-specific recommendations:

  Application	Key Considerations
  Western Blot	Use freshly prepared samples; include positive controls (doxorubicin-treated cells); follow recommended antibody dilutions (1:500-1:2000)
  IHC	Optimize antigen retrieval; use recommended dilutions (1:100-1:300); include control tissues
  ELISA	Follow recommended high dilution (1:20000) to minimize background

• Storage and handling:

  • Store the antibody at -20°C for long-term storage

  • For frequent use, aliquot and store at 4°C for up to one month

  • Avoid repeated freeze-thaw cycles

• Controls integration:

  • Always include appropriate positive controls (doxorubicin-treated cells)

  • Use negative controls (p53-null cells, S366A mutant expressing cells)

  • Consider phosphatase treatment controls for definitive validation

Following this standardized workflow will help ensure consistent and reproducible results when working with Phospho-TP53 (S366) antibody in various research applications.